Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2004 2
2005 3
2006 4
2008 1
2009 2
2010 2
2012 3
2013 3
2015 2
2016 6
2017 3
2018 4
2019 3
2020 6
2021 5
2022 3
2023 4
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

56 results

Results by year

Filters applied: . Clear all
Page 1
Charting the Course in Sequencing Antibody-Drug Conjugates in Breast Cancer.
Saltalamacchia G, Torrisi R, De Sanctis R, Masci G, Miggiano C, Gaudio M, Benvenuti C, Jacobs F, Gerosa R, Santoro A, Zambelli A. Saltalamacchia G, et al. Among authors: masci g. Biomedicines. 2024 Feb 23;12(3):500. doi: 10.3390/biomedicines12030500. Biomedicines. 2024. PMID: 38540113 Free PMC article. Review.
Cyclin-dependent kinase 2 (CDK2) inhibitors and others novel CDK inhibitors (CDKi) in breast cancer: clinical trials, current impact, and future directions.
Gerosa R, De Sanctis R, Jacobs F, Benvenuti C, Gaudio M, Saltalamacchia G, Torrisi R, Masci G, Miggiano C, Agustoni F, Pedrazzoli P, Santoro A, Zambelli A. Gerosa R, et al. Among authors: masci g. Crit Rev Oncol Hematol. 2024 Apr;196:104324. doi: 10.1016/j.critrevonc.2024.104324. Epub 2024 Mar 8. Crit Rev Oncol Hematol. 2024. PMID: 38462150 Free article. Review.
A New Risk Prediction Model for Venous Thromboembolism and Death in Ambulatory Lung Cancer Patients.
Gomez-Rosas P, Giaccherini C, Russo L, Verzeroli C, Gamba S, Tartari CJ, Bolognini S, Ticozzi C, Schieppati F, Barcella L, Sarmiento R, Masci G, Tondini C, Petrelli F, Giuliani F, D'Alessio A, Minelli M, De Braud F, Santoro A, Labianca R, Gasparini G, Marchetti M, Falanga A, On Behalf Of The Hypercan Investigators. Gomez-Rosas P, et al. Among authors: masci g. Cancers (Basel). 2023 Sep 15;15(18):4588. doi: 10.3390/cancers15184588. Cancers (Basel). 2023. PMID: 37760562 Free PMC article.
Nebivolol versus placebo in patients undergoing anthracyclines (CONTROL Trial): rationale and study design.
Cannata F, Stefanini G, Carlo-Stella C, Chiarito M, Figliozzi S, Novelli L, Lisi C, Bombace S, Panico C, Cosco F, Corrado F, Masci G, Mazza R, Ricci F, Monti L, Ferrante G, Santoro A, Francone M, da Costa BR, Jüni P, Condorelli G. Cannata F, et al. Among authors: masci g. J Cardiovasc Med (Hagerstown). 2023 Jul 1;24(7):469-474. doi: 10.2459/JCM.0000000000001491. J Cardiovasc Med (Hagerstown). 2023. PMID: 37285278 Clinical Trial.
Utility of the Khorana and the new-Vienna CATS prediction scores in cancer patients of the HYPERCAN cohort.
Verzeroli C, Giaccherini C, Russo L, Bolognini S, Gamba S, Tartari CJ, Schieppati F, Ticozzi C, Vignoli A, Masci G, Sarmiento R, Spinelli D, Malighetti P, Tondini C, Petrelli F, Giuliani F, D'Alessio A, Gasparini G, Minelli M, De Braud F, Santoro A, Labianca R, Marchetti M, Falanga A; HYPERCAN Investigators. Verzeroli C, et al. Among authors: masci g. J Thromb Haemost. 2023 Jul;21(7):1869-1881. doi: 10.1016/j.jtha.2023.03.037. Epub 2023 Apr 11. J Thromb Haemost. 2023. PMID: 37054917 Free article.
Thrombin Generation and D-Dimer for Prediction of Disease Progression and Mortality in Patients with Metastatic Gastrointestinal Cancer.
Giaccherini C, Verzeroli C, Russo L, Gamba S, Tartari CJ, Bolognini S, Schieppati F, Ticozzi C, Sarmiento R, Celio L, Masci G, Tondini C, Petrelli F, Giuliani F, D'Alessio A, De Braud F, Santoro A, Labianca R, Gasparini G, Marchetti M, Falanga A; HYPERCAN Investigators. Giaccherini C, et al. Among authors: masci g. Cancers (Basel). 2022 Sep 6;14(18):4347. doi: 10.3390/cancers14184347. Cancers (Basel). 2022. PMID: 36139507 Free PMC article.
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.
Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, Tsurutani J, Ueno NT, Prat A, Chae YS, Lee KS, Niikura N, Park YH, Xu B, Wang X, Gil-Gil M, Li W, Pierga JY, Im SA, Moore HCF, Rugo HS, Yerushalmi R, Zagouri F, Gombos A, Kim SB, Liu Q, Luo T, Saura C, Schmid P, Sun T, Gambhire D, Yung L, Wang Y, Singh J, Vitazka P, Meinhardt G, Harbeck N, Cameron DA; DESTINY-Breast04 Trial Investigators. Modi S, et al. N Engl J Med. 2022 Jul 7;387(1):9-20. doi: 10.1056/NEJMoa2203690. Epub 2022 Jun 5. N Engl J Med. 2022. PMID: 35665782 Free PMC article. Clinical Trial.
56 results